-

908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will report financial results for the second quarter 2025 before market open on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

Contacts

Media
Barbara Russo
brusso@908devices.com

Investor
Carrie Mendivil
IR@908devices.com

908 Devices Inc.

NASDAQ:MASS

Release Versions

Contacts

Media
Barbara Russo
brusso@908devices.com

Investor
Carrie Mendivil
IR@908devices.com

More News From 908 Devices Inc.

908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. “We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile,” said Kevin J. Knopp, CEO and Co-founder. “We deli...

908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors...

908 Devices to Participate in the Canaccord Genuity 45th Annual Growth Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming Canaccord Genuity 45th Annual Growth Conference. 908 Devices’ management is scheduled to present on Wednesday, August 13 at 1 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section...
Back to Newsroom